Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00070187 · ClinicalTrials.gov registry record · Phase 2

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

A Phase 2 study of Lymphoma, sponsored by Children's Oncology Group.

Compiled by PlainTrial · August 8, 2026

Completed
Registry status: Phase 2
Development phase: 24
Enrollment target: 20
Study locations

NCT00070187: Completed Phase 2 study of Lymphoma, sponsored by Children's Oncology Group.

NCT00070187 is a Phase 2 study of Lymphoma that has completed, run by Children's Oncology Group. The registered enrollment target is 24 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00070187, a Phase 2 study of Lymphoma, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status: Phase 2
Development phase: 24 participants
Enrollment target: 20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy using cyclosporine, interferon gamma, and interleukin-2 after stem cell transplantation may help the transplanted cells make an immune response and kill any remaining cancer cells. It is not yet known whether high-dose chemotherapy followed by autologous stem cell transplantation is more effective with or without immunotherapy. PURPOSE: This randomized phase II/III trial is studying how well high-dose chemotherapy followed by autologous stem cell transplantation, cyclosporine, interferon gamma, and interleukin-2 works and compares it to high-dose chemotherapy followed by autologous stem cell transplantation only in treating patients with refractory or relapsed Hodgkin's lymphoma.

Primary Outcome

Death, excluding death due to disease, during the period of time from Day 0 (transplant) through Day 100 post transplant.

Conditions Studied

Lymphoma

Interventions

DRUG carmustine
BIOLOGICAL aldesleukin
BIOLOGICAL filgrastim
DRUG cyclosporine
BIOLOGICAL recombinant interferon gamma

Study Locations (20)

Florida

University of Florida Shands Cancer Center - Gainesville
Nemours Children's Clinic - Jacksonville
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami Children's Hospital - Miami
All Children's Hospital - St. Petersburg
St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa
Kaplan Cancer Center at St. Mary's Medical Center - West Palm Beach

California

Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
Children's Hospital and Research Center - Oakland - Oakland
Children's Hospital of Orange County - Orange
Kaiser Permanente Medical Center - Oakland - Sacramento

Illinois

Children's Memorial Hospital - Chicago - Chicago
Southern Illinois University School of Medicine - Springfield

Alabama

Comprehensive Cancer Center at University of Alabama at Birmingham - Birmingham

Arizona

Phoenix Children's Hospital - Phoenix

Arkansas

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Delaware

Alfred I. duPont Hospital for Children - Wilmington

District of Columbia

Children's National Medical Center - Washington D.C.

Trial Details

Field	Value
Enrollment Target	24 participants
Start Date	2003-11
Phase	Phase 2

Children's Oncology Group

342 total trials

What the finished NCT00070187 record still lists

NCT00070187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which carmustine is the first listed.

NCT00070187 names 20 study sites across 10 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00070187 about?

NCT00070187 is a clinical study titled "Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy u...

What is the current status of trial NCT00070187?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2003-11.

What conditions does trial NCT00070187 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00070187?

The interventions under investigation include: carmustine (DRUG), aldesleukin (BIOLOGICAL), filgrastim (BIOLOGICAL), cyclosporine (DRUG), recombinant interferon gamma (BIOLOGICAL).

Who is sponsoring clinical trial NCT00070187?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00070187 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00070187's enrollment target sits among peer trials

24 235th of 299 higher than 61 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00070187, the US trial registry maintained by the National Library of Medicine. NCT00070187 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.